scholarly journals Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

Blood ◽  
1982 ◽  
Vol 60 (2) ◽  
pp. 454-462 ◽  
Author(s):  
J Yates ◽  
O Glidewell ◽  
P Wiernik ◽  
MR Cooper ◽  
D Steinberg ◽  
...  
Keyword(s):  
Gastrointestinal Tract ◽  
Complete Remission ◽  
Maintenance Therapy ◽  
Continuous Infusion ◽  
Cytosine Arabinoside ◽  
Acute Myelocytic Leukemia ◽  
Relative Efficacy ◽  
Myelocytic Leukemia ◽  
Anthracycline Dose ◽  
Better Than

A randomized comparison of the relative efficacy and toxicity of daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m, given on the first 3 days of a 7-day continuous infusion of cytosine arabinoside (ara-C) at 100 mg/sq m/day, shows the outcome to be dependent on anthracycline, dose, and patient age. DNR 45 is significantly better than DNR 30 or ADM 30 for inducing complete remissions (CR) in patients younger than 60 yr, (72%, 59%, 58% CRs, respectively). DNR 30 is better than DNR 45 or ADM 30 for inducing CR in patients older than 60 yr (47%, 31%, 35%, respectively). There was a corresponding shift in the induction mortality for the age, dose, and anthracycline groups. Adriamycin was significantly more toxic to the gastrointestinal tract than daunorubicin. The duration of complete remission, with cyclic courses of maintenance therapy, was independent of the patient's age, the dose, or choice of anthracycline used in induction, and of whether the maintenance courses were given every 4 wk or every 8 wk.

scholarly journals Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

Blood ◽  
1982 ◽  
Vol 60 (2) ◽  
pp. 454-462 ◽  
Author(s):  
J Yates ◽  
O Glidewell ◽  
P Wiernik ◽  
MR Cooper ◽  
D Steinberg ◽  
...  
Keyword(s):  
Gastrointestinal Tract ◽  
Complete Remission ◽  
Maintenance Therapy ◽  
Continuous Infusion ◽  
Cytosine Arabinoside ◽  
Acute Myelocytic Leukemia ◽  
Relative Efficacy ◽  
Myelocytic Leukemia ◽  
Anthracycline Dose ◽  
Better Than

Abstract A randomized comparison of the relative efficacy and toxicity of daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m, given on the first 3 days of a 7-day continuous infusion of cytosine arabinoside (ara-C) at 100 mg/sq m/day, shows the outcome to be dependent on anthracycline, dose, and patient age. DNR 45 is significantly better than DNR 30 or ADM 30 for inducing complete remissions (CR) in patients younger than 60 yr, (72%, 59%, 58% CRs, respectively). DNR 30 is better than DNR 45 or ADM 30 for inducing CR in patients older than 60 yr (47%, 31%, 35%, respectively). There was a corresponding shift in the induction mortality for the age, dose, and anthracycline groups. Adriamycin was significantly more toxic to the gastrointestinal tract than daunorubicin. The duration of complete remission, with cyclic courses of maintenance therapy, was independent of the patient's age, the dose, or choice of anthracycline used in induction, and of whether the maintenance courses were given every 4 wk or every 8 wk.

A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia

1979 ◽  
Vol 6 (3) ◽  
pp. 261-277 ◽  
Author(s):  
Peter H. Wiernik ◽  
Oliver J. Glidewell ◽  
H. Clark Hoagland ◽  
Kurt W. Brunner ◽  
Charles L. Spurr ◽  
...  
Keyword(s):  
Cytosine Arabinoside ◽  
Comparative Trial ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia

scholarly journals Acute nonlymphocytic leukemia in adults: correlations with Q-banded chromosomes

Blood ◽  
1976 ◽  
Vol 48 (1) ◽  
pp. 9-21 ◽  
Author(s):  
HM Golomb ◽  
J Vardiman ◽  
JD Rowley
Keyword(s):  
Complete Remission ◽  
Median Survival ◽  
Treated Group ◽  
Chromosome Abnormalities ◽  
Acute Myelocytic Leukemia ◽  
Acute Nonlymphocytic Leukemia ◽  
Survival Times ◽  
Myelocytic Leukemia ◽  
Group I ◽  
Group Ii

Abstract Chromosome banding patterns were obtained for 50 of 55 consecutive adult patients with acute nonlymphocytic leukemia during a 5-yr period. Twenty-two of the 50 cases were diagnosed as acute myelocytic leukemia (AML), 24 as acute myelomonocytic leukemia (AMMol), 2 as acute promyelocytic leukemia (APL), and 2 as erythroleukemia. Twenty-five patients had initial chromosome abnormalities during the course of the disease. The median survival of patients with normal chromosomes initially (group I) was 10 mo, whereas that of patients with abnormal chromosomes initially (group II) was 2 mo. Similar times were obtained for treated patients with AML and AMMol. However, when the AML patients were separated into those with and those without a chromosome abnormality, the median survival times were markedly different (2 mo versus 18 mo, respectively). Patients with AMMol demonstrated no difference in median survival times when subgrouped according to the presence or absence of chromosome abnormalities. The treated group II patients whose marrow samples had only abnormal metaphases had a poorer response (10% complete remission) and median survival (2 mo) than the group II patients who had at least one normal metaphase (42% complete remission with a median survival of 9 mo). The two cases of APL demonstrated a deletion of the long arm of No. 17 which occurred in the same region of the chromosome in each case. Both patients had similar clinical histories, with disseminated intravascular coagulation, and neither responded to therapy.

scholarly journals A two-step timed sequential treatment for acute myelocytic leukemia

Blood ◽  
1989 ◽  
Vol 74 (5) ◽  
pp. 1499-1506 ◽  
Author(s):  
RB Geller ◽  
PJ Burke ◽  
JE Karp ◽  
RL Humphrey ◽  
HG Braine ◽  
...  
Keyword(s):  
Overall Survival ◽  
Complete Remission ◽  
De Novo ◽  
Remission Rate ◽  
Disease Free Survival ◽  
Acute Myelocytic Leukemia ◽  
Significant Prognostic Factor ◽  
Myelocytic Leukemia ◽  
De Novo Aml ◽  
To Receive

Abstract Since 1980, adults with acute myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55%. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of greater than 40% at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). This first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76% for de novo AML and 54% for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age less than or equal to 55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively.

scholarly journals Prediction of response to chemotherapy in acute myelocytic leukemia

Blood ◽  
1980 ◽  
Vol 56 (3) ◽  
pp. 361-367 ◽  
Author(s):  
HD Preisler
Keyword(s):  
Cytosine Arabinoside ◽  
Chemotherapeutic Agents ◽  
Leukemic Cells ◽  
Acute Myelocytic Leukemia ◽  
Metabolic Resistance ◽  
Clear Cut ◽  
Myelocytic Leukemia ◽  
Response To Chemotherapy

Abstract Marrow specimens obtained from 23 patients with acute myelocytic leukemia were exposed to cytosine arabinoside and/or daunorubicin in vitro, and the effects of these agents on colony formation in vitro was determined. Thymidine suicide indices were determined as well, which permitted a distinction to be made between kinetic and metabolic resistance to cytosine arabinoside. The sensitivity of the colony- forming cells to the two chemotherapeutic agents did not correlate with each other, indicating that sensitivity to each was independently determined. The relationship between in vitro sensitivity to daunorubicin and cytosine arabinoside and response to 25 courses of in vivo therapy with these two agents administered to 21 patients was determined. These studies indicated a clear-cut relationship between in vitro drug sensitivity and in vivo response with patients whose leukemic cells were sensitive to both agents entering complete remission, whereas patients whose leukemic cells were insensitive to one or both drugs in vitro failed to enter remission.

Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia

Cancer ◽  
1975 ◽  
Vol 36 (5) ◽  
pp. 1560-1566 ◽  
Author(s):  
Robert W. Carey ◽  
Manuel Ribas-Mundo ◽  
Rose Ruth Ellison ◽  
Oliver Glidewell ◽  
Stanley T. Lee ◽  
...  
Keyword(s):  
Comparative Study ◽  
Cytosine Arabinoside ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document